BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33361765)

  • 1. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
    Zhou T; Li S; Xiang D; Liu J; Sun W; Cui X; Ning B; Li X; Cheng Z; Jiang W; Zhang C; Liang X; Li L; Cheng X; Hui L; Wang H; Ding J
    Signal Transduct Target Ther; 2020 Dec; 5(1):296. PubMed ID: 33361765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA m
    Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
    EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
    Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
    Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
    Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
    Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
    Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
    Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.
    Quagliata L; Quintavalle C; Lanzafame M; Matter MS; Novello C; di Tommaso L; Pressiani T; Rimassa L; Tornillo L; Roncalli M; Cillo C; Pallante P; Piscuoglio S; Ng CK; Terracciano LM
    Lab Invest; 2018 Jan; 98(1):95-105. PubMed ID: 29035381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N
    Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
    Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
    Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
    Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
    Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
    Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.